HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir (STO:MVIRB)
Financial summary
Third quarter 2015 (2014)
· Net turnover totalled SEK 111.5 million (617.8 m), of which SEK 69.0 million (516.4 m) comprised royalties for simeprevir, where of SEK 11.5 million referred to past periods.
